Search Results - "Augustin, Ryan C"

Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy by Augustin, Ryan C., Leone, Robert D., Naing, Aung, Fong, Lawrence, Bao, Riyue, Luke, Jason J.

“…Increasing evidence supports targeting the adenosine pathway in immuno-oncology with several clinical programs directed at adenosine A2 receptor (A2AR, A2BR),…”
Get full text

Targeting Cbl-b in cancer immunotherapy by Augustin, Ryan C., Bao, Riyue, Luke, Jason J.

“…Cancer immunotherapy with immune-checkpoint blockade has improved the outcomes of patients with various malignancies, yet a majority do not benefit or develop…”
Get full text

Metformin is associated with improved clinical outcomes in patients with melanoma: a retrospective, multi-institutional study by Augustin, Ryan C, Huang, Ziyu, Ding, Fei, Zhai, Shuyan, McArdle, Jennifer, Santisi, Anthony, Davis, Michael, Sander, Cindy, Davar, Diwakar, Kirkwood, John M, Delgoffe, Greg M, Warner, Allison Betof, Najjar, Yana G

“…Pre-clinical studies have shown that metformin reduces intratumoral hypoxia, improves T-cell function, and increases sensitivity to PD-1 blockade, and…”
Get full text

Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma by Augustin, Ryan C, Newman, Sarah, Li, Aofei, Joy, Marion, Lyons, Maureen, Pham, Mary P, Lucas, Peter, Smith, Katelyn, Sander, Cindy, Isett, Brian, Davar, Diwakar, Najjar, Yana G, Zarour, Hassane M, Kirkwood, John M, Luke, Jason John, Bao, Riyue

“…Acral melanoma (AM) has distinct characteristics as compared with cutaneous melanoma and exhibits poor response to immune checkpoint inhibitors (ICIs)…”
Get full text

Characteristics of the Tumor Microenvironment That Influence Immune Cell Functions: Hypoxia, Oxidative Stress, Metabolic Alterations by Augustin, Ryan C, Delgoffe, Greg M, Najjar, Yana G

“…Immunotherapy (IMT) is now a core component of cancer treatment, however, many patients do not respond to these novel therapies. Investigating the resistance…”
Get full text

PD-1 Monotherapy Reigns Supreme in Adjuvant Melanoma…But for How Long? by Augustin, Ryan C, Luke, Jason J

“…The results of CheckMate-238 led to the original FDA approval of anti-PD-1 therapy in high-risk, resectable melanoma. In this CCR Translations, we discuss the…”
Get full text

Induction Exposure Dose of Ipilimumab and Failure of Adjuvant Nivolumab Plus Ipilimumab in Melanoma by Augustin, Ryan C, Luke, Jason J

Get full text

Top advances of the year: Melanoma by Augustin, Ryan C., Luke, Jason J.

“…This commentary highlights the key, recent advances made in the field of melanoma. Although significant gains have been made, particularly for resectable…”
Get full text

Facts and Hopes in Using Omics to Advance Combined Immunotherapy Strategies by Augustin, Ryan C, Cai, Wesley L, Luke, Jason J, Bao, Riyue

“…The field of oncology has been transformed by immune checkpoint inhibitors (ICI) and other immune-based agents; however, many patients do not receive a durable…”
Get full text

Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma by Augustin, Ryan C., Luke, Jason J.

“…With the development of effective BRAF -targeted and immune-checkpoint immunotherapies for metastatic melanoma, clinical trials are moving these treatments…”
Get full text

Old Dog, New Trick: A Tumor-Intrinsic Role for PD-1 in Chemoresistant Tumor Subclones by Augustin, Ryan C, Bao, Riyue, Luke, Jason J

“…Programmed cell death protein 1 (PD-1) is a well-known driver of immunosuppression and lymphocyte-associated disease progression. Increasing evidence suggests…”
Get full text

Morning Report for all: the use of podcasts to disseminate clinical reasoning tools by Augustin, Ryan C, Bonifacino, Eliana, Tilstra, Sarah A

Get full text

Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma by Hahn, Andrew W, Menk, Ashley V, Rivadeneira, Dayana B, Augustin, Ryan C, Xu, Mingchu, Li, Jun, Wu, Xiaogang, Mishra, Aditya K, Gide, Tuba N, Quek, Camelia, Zang, Yan, Spencer, Christine N, Menzies, Alexander M, Daniel, Carrie R, Hudgens, Courtney W, Nowicki, Theodore, Haydu, Lauren E, Khan, M A Wadud, Gopalakrishnan, Vancheswaran, Burton, Elizabeth M, Malke, Jared, Simon, Julie M, Bernatchez, Chantale, Putluri, Nagireddy, Woodman, Scott E, Vashisht Gopal, Y N, Guerrieri, Renato, Fischer, Grant M, Wang, Jian, Wani, Khalida M, Thompson, John F, Lee, Jeffrey E, Hwu, Patrick, Ajami, Nadim, Gershenwald, Jeffrey E, Long, Georgina V, Scolyer, Richard A, Tetzlaff, Michael T, Lazar, Alexander J, Schadendorf, Dirk, Wargo, Jennifer A, Kirkwood, John M, DeBerardinis, Ralph J, Liang, Han, Futreal, Andrew, Zhang, Jianhua, Wilmott, James S, Peng, Weiyi, Davies, Michael A, Delgoffe, Greg M, Najjar, Yana G, McQuade, Jennifer L

“…Overweight/obese (OW/OB) patients with metastatic melanoma unexpectedly have improved outcomes with immune checkpoint inhibitors (ICI) and BRAF-targeted…”
Get full text

Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis by Kuang, Chaoyuan, Park, Yongseok, Augustin, Ryan C, Lin, Yan, Hartman, Douglas J, Seigh, Lindsey, Pai, Reetesh K, Sun, Weijing, Bahary, Nathan, Ohr, James, Rhee, John C, Marks, Stanley M, Beasley, H Scott, Shuai, Yongli, Herman, James G, Zarour, Hassane M, Chu, Edward, Lee, James J, Krishnamurthy, Anuradha

“…DNA mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) is not responsive to pembrolizumab monotherapy. DNA methyltransferase inhibitors can…”
Get full text

Goals of Care and Patient-Centric Outcomes for Checkpoint Inhibitor Immunotherapy in Patients With Limited Performance Status by Augustin, Ryan C, Luke, Jason J

Get more information

Residency and Fellowship Program Leaders' Perceptions of Virtual Recruitment and Interviewing by Das, Anjali J, Augustin, Ryan C, Corbelli, Jennifer A, Bump, Gregory M

“…Virtual recruitment is a new and more cost-effective alternative to traditional in-person recruitment in academic medicine. However, little is known about the…”
Get full text

888 Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma by Augustin, Ryan C, Brodeur, Sarah, Li, Aofei, Joy, Marion, Lyons, Maureen, Pham, Mary, Lucas, Peter C, Smith, Katelyn, Sander, Cindy, Isett, Brian, Davar, Diwakar, Najjar, Yana G, Zarour, Hassane, Kirkwood, John M, Luke, Jason J, Bao, Riyue

“…BackgroundAcral melanoma (AM) is a rare cancer with distinct genotypic and phenotypic characteristics as compared to cutaneous melanoma (CM). While UV…”
Get full text

PD1 monotherapy reigns supreme in adjuvant melanoma…but for how long? by Augustin, Ryan C., Luke, Jason J.

“…The results of CheckMate-238 led to the original FDA approval of anti-PD1 therapy in high-risk, resectable melanoma. In this CCR Translations, we discuss the…”
Get full text

Old dog, new trick: a tumor-intrinsic role for PD1 in chemoresistant tumor subclones by Augustin, Ryan C., Bao, Riyue, Luke, Jason J.

“…Programmed cell death protein 1 (PD1) is a well-known driver of immuno-suppression and lymphocyte-associated disease progression. Increasing evidence suggests…”
Get full text